Related Experiment Video

Updated: Jul 6, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Familial hypercholesterolemia: current treatment and advances in management

Roeland Huijgen1, Maud N Vissers, Joep C Defesche

  • 1Academic Medical Center, Department of Vascular Medicine, Meibergreef 9 (Room F4-146), 1105 AZ, Amsterdam, The Netherlands. r.huijgen@amc.uva.nl

Expert Review of Cardiovascular Therapy
|April 12, 2008
PubMed

Insights

Heterozygous familial hypercholesterolemia (HeFH) causes high LDL-cholesterol and early heart disease. This review discusses statins and alternative treatments for managing HeFH effectively.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Familial hypercholesterolemia (FH) is an underdiagnosed genetic disorder.
  • HeFH leads to elevated LDL-cholesterol, increasing premature cardiovascular disease risk.
  • Effective management of HeFH is crucial for preventing cardiovascular events.

Purpose of the Study:

  • To review current and alternative treatment options for heterozygous familial hypercholesterolemia.
  • To highlight the importance of diagnosis and treatment intensification.
  • To provide an overview of therapeutic strategies for managing elevated LDL-cholesterol in HeFH patients.

Main Methods:

  • Literature review of studies on familial hypercholesterolemia management.
  • Analysis of treatment guidelines and clinical trial data.
  • Discussion of pharmacological interventions, including statins and alternative therapies.

Main Results:

  • Statins are the primary treatment for HeFH.
  • Many patients require additional therapies to reach LDL-cholesterol goals.
  • Alternative treatments offer options for statin-intolerant patients or those with suboptimal response.

Conclusions:

  • Optimal management of HeFH requires timely diagnosis and effective LDL-cholesterol lowering.
  • A stepwise approach involving statins and alternative therapies is essential.
  • Addressing under-diagnosis and under-treatment is critical for reducing cardiovascular risk in HeFH.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...